Catalona W J, Smolev J K, Harty J I
J Urol. 1975 Dec;114(6):922-6. doi: 10.1016/s0022-5347(17)67175-1.
To evaluate the prognostic significance of host immunocompetence in urologic cancer patients, the subsequent clinical course of 95 patients was determined a year after skin testing with dinitrochlorobenzene. A close correlation was demonstrated between dinitrochlorobenzene reactivity and prognosis among 38 transitional carcinoma patients. Of 19 patients with impaired reactivity 13 had tumor recurrences and 11 of these died of cancer within 1 year. Only 5 of 19 patients with normal dinitrochlorobenzene reactivity had recurrences and none died during the same interval. Although not statistically significant, similar results were observed among 10 renal cell carcinoma patients of whom 3 of 5 with impaired dinitrochlorobenzene reactivity had tumor recurrences, while 4 of 5 with normal reactivity remained free of tumor. One testis tumor patient with impaired dinitrochlorobenzene reactivity died of cancer, while 3 of 4 with normal reactivity remained free of tumor. Similarly, 1 patient with carcinoma of the penis with impaired dinitrochlorobenzene reactivity died of cancer, while 2 of 3 with normal reactivity remained free of tumor. In contrast, reactivity to dinitrochlorobenzene did not correlate with the clinical course of 38 prostatic carcinoma patients. Ten of 19 patients with normal dinitrochlorobenzene reactivity and 9 of 19 with impaired reactivity were dead or had symptomatic recurrences within 1 year, while 9 of 19 with normal reactivity and 10 of 19 with impaired reactivity were either free of tumor or asymptomatic. However, a trend toward a correlation between dinitrochlorobenzene reactivity and tumor progression was observed among patients not receiving endocrine therapy. The differences with respect to the prognostic significance of host immunocompetence between transitional carcinoma patients and those with prostatic carcinoma may be explained by fundamental differences in the biologic properties of these tumors, especially the endocrine sensitivity of prostatic carcinoma.
为评估宿主免疫能力对泌尿系统癌症患者预后的意义，在用二硝基氯苯进行皮肤试验一年后，确定了95例患者随后的临床病程。在38例移行细胞癌患者中，二硝基氯苯反应性与预后之间存在密切相关性。19例反应性受损的患者中有13例出现肿瘤复发，其中11例在1年内死于癌症。19例二硝基氯苯反应性正常的患者中只有5例出现复发，且在同一时期内无人死亡。在10例肾细胞癌患者中也观察到了类似结果，尽管无统计学意义，5例二硝基氯苯反应性受损的患者中有3例出现肿瘤复发，而5例反应性正常的患者中有4例未发生肿瘤。1例二硝基氯苯反应性受损的睾丸肿瘤患者死于癌症，而4例反应性正常的患者中有3例未发生肿瘤。同样，1例二硝基氯苯反应性受损的阴茎癌患者死于癌症，而3例反应性正常的患者中有2例未发生肿瘤。相比之下，二硝基氯苯反应性与38例前列腺癌患者的临床病程无关。19例二硝基氯苯反应性正常的患者中有10例以及19例反应性受损的患者中有9例在1年内死亡或出现有症状的复发，而19例反应性正常的患者中有9例以及19例反应性受损的患者中有10例无肿瘤或无症状。然而，在未接受内分泌治疗的患者中，观察到二硝基氯苯反应性与肿瘤进展之间存在相关趋势。移行细胞癌患者与前列腺癌患者在宿主免疫能力预后意义方面的差异，可能是由这些肿瘤生物学特性的根本差异所解释的，尤其是前列腺癌的内分泌敏感性。
